title: Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.
abstract: The structural integrity and conformational stability of various IgG1-Fc proteins produced from the yeast Pichia pastoris with different glycosylation site occupancy (di-, mono-, and nonglycosylated) were determined. In addition, the physical stability profiles of three different forms of nonglycosylated Fc molecules (varying amino-acid residues at site 297 in the CH 2 domain due to the point mutations and enzymatic digestion of the Fc glycoforms) were also examined. The physical stability of these IgG1-Fc glycoproteins was examined as a function of pH and temperature by high-throughput biophysical analysis using multiple techniques combined with data visualization tools (three index empirical phase diagrams and radar charts). Across the pH range of 4.0-6.0, the di- and monoglycosylated forms of the IgG1-Fc showed the highest and lowest levels of physical stability, respectively, with the nonglycosylated forms showing intermediate stability depending on solution pH. In the aglycosylated Fc proteins, the introduction of Asp (D) residues at site 297 (QQ vs. DN vs. DD forms) resulted in more subtle changes in structural integrity and physical stability depending on solution pH. The utility of evaluating the conformational stability profile differences between the various IgG1-Fc glycoproteins is discussed in the context of analytical comparability studies.
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Alsenaidy
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: Solomon Z
authors.initials: SZ
authors.lastname: Okbazghi
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: Jae Hyun
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: Sangeeta B
authors.initials: SB
authors.lastname: Joshi
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: C Russell
authors.initials: CR
authors.lastname: Middaugh
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Tolbert
authors.affiliation: Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
authors.forename: David B
authors.initials: DB
authors.lastname: Volkin
mesh_terms: D001216:Asparagine / Q000737:chemistry*; D015153:Blotting, Western; D002850:Chromatography, Gel; D004591:Electrophoresis, Polyacrylamide Gel; D005998:Glycine / Q000737:chemistry*; D006031:Glycosylation; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry*; D007074:Immunoglobulin G / Q000737:chemistry*; D021241:Spectrometry, Mass, Electrospray Ionization; D013056:Spectrophotometry, Ultraviolet
chemical_list: D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D001216:Asparagine; D005998:Glycine
keywords: Fc; IgG; conformation; formulation; glycosylation; mass spectrometry; monoclonal antibody; spectroscopy; stability
references.citation: MAbs. 2010 Nov-Dec;2(6):613-24
references.pmid: 20818176
references.citation: Biochemistry. 2001 Jul 31;40(30):8868-76
references.pmid: 11467948
references.citation: J Pharm Sci. 2013 Jan;102(1):43-51
references.pmid: 23160989
references.citation: J Pharm Sci. 2012 Nov;101(11):4107-17
references.pmid: 22927056
references.citation: Eur J Pharm Sci. 2008 Feb 5;33(2):120-7
references.pmid: 18162379
references.citation: Anal Biochem. 2009 Sep 15;392(2):145-54
references.pmid: 19497295
references.citation: Protein Sci. 2012 Oct;21(10):1540-53
references.pmid: 22898970
references.citation: Glycoconj J. 2013 Jan;30(1):11-22
references.pmid: 22532006
references.citation: Biologicals. 2013 May;41(3):131-47
references.pmid: 23146362
references.citation: Glycobiology. 2011 Jul;21(7):949-59
references.pmid: 21421994
references.citation: Biochemistry. 2013 May 14;52(19):3376-89
references.pmid: 23594236
references.citation: Biotechnol J. 2011 Jan;6(1):38-44
references.pmid: 20949542
references.citation: J Proteome Res. 2013 Feb 1;12(2):821-31
references.pmid: 23298168
references.citation: Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74
references.pmid: 21768335
references.citation: Blood. 1997 Aug 1;90(3):1109-14
references.pmid: 9242542
references.citation: J Biol Chem. 2012 Jan 6;287(2):1381-96
references.pmid: 22084250
references.citation: Glycobiology. 2011 Aug;21(8):1087-96
references.pmid: 21470983
references.citation: J Am Soc Mass Spectrom. 2008 Nov;19(11):1643-54
references.pmid: 18707900
references.citation: Biochemistry. 2012 Dec 18;51(50):10056-65
references.pmid: 23078371
references.citation: Anal Chem. 2012 Apr 3;84(7):3040-8
references.pmid: 22360375
references.citation: J Chromatogr A. 2010 Oct 15;1217(42):6496-502
references.pmid: 20828701
references.citation: J Pharm Sci. 2013 Jun;102(6):1724-1733
references.pmid: 23568791
references.citation: Trends Biotechnol. 2010 Oct;28(10):509-16
references.pmid: 20691488
references.citation: J Am Chem Soc. 2009 Sep 30;131(38):13616-8
references.pmid: 19728704
references.citation: Biologicals. 2011 Jan;39(1):9-22
references.pmid: 20888784
references.citation: Mol Cell Proteomics. 2013 Apr;12(4):856-65
references.pmid: 23325769
references.citation: Protein Expr Purif. 2002 Feb;24(1):90-8
references.pmid: 11812228
references.citation: Protein Sci. 2012 Mar;21(3):418-32
references.pmid: 22113934
references.citation: MAbs. 2013 Jul-Aug;5(4):513-7
references.pmid: 23727858
references.citation: BioDrugs. 2013 Oct;27(5):495-507
references.pmid: 23649935
references.citation: Mol Cell Proteomics. 2010 Aug;9(8):1716-28
references.pmid: 20103567
references.citation: Biologicals. 2011 Jul;39(4):205-10
references.pmid: 21723741
references.citation: Biochem Biophys Res Commun. 2006 Mar 17;341(3):797-803
references.pmid: 16442075
references.citation: Annu Rev Immunol. 2007;25:21-50
references.pmid: 17029568
references.citation: J Pharm Sci. 2013 Jul;102(7):2136-51
references.pmid: 23620222
references.citation: Mol Pharm. 2012 Apr 2;9(4):791-802
references.pmid: 22352470
references.citation: Nat Biotechnol. 2012 Dec;30(12):1191-7
references.pmid: 23222785
references.citation: Nat Rev Drug Discov. 2012 Jun 29;11(7):527-40
references.pmid: 22743980
references.citation: Nat Methods. 2012 Jul;9(7):671-5
references.pmid: 22930834
references.citation: Immunology. 1986 Feb;57(2):311-7
references.pmid: 3081439
references.citation: J Pharm Sci. 2013 Nov;102(11):3942-56
references.pmid: 24114789
references.citation: J Pharm Sci. 2010 Jun;99(6):2582-97
references.pmid: 20039394
references.citation: ACS Chem Biol. 2012 Sep 21;7(9):1596-602
references.pmid: 22747430
references.citation: Nat Rev Drug Discov. 2009 Mar;8(3):226-34
references.pmid: 19247305
references.citation: Anal Chem. 2009 Apr 1;81(7):2644-51
references.pmid: 19265386